Trial Profile
A phase II study of transdermal granisetron for the prevention of chemotherapy-induced nausea and vomiting in patients with metastatic colorectal cancer and high risk of bowel obstruction
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2016
Price :
$35
*
At a glance
- Drugs Granisetron (Primary) ; Metoclopramide (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Adverse reactions; Therapeutic Use
- 06 Dec 2016 New trial record
- 11 Oct 2016 Results of exploratory analysis (n=32) presented at the 41st European Society for Medical Oncology Congress.